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Abstract
Background Impressive progress in new therapeutic options has been made for psoriasis. Treatments include topical
steroids, phototherapy, conventional, synthetic disease-modifying drugs and an expanding list of biologics.
Objective The primary objective of this work was to collect evidence for the creation of practice guidelines for systemic
treatment of psoriasis (BETA-PSO: Belgian Evidence-based Treatment Advice in Psoriasis).
Methods Evidence-based recommendations were formulated using a quasi-Delphi methodology after a systematic
search of the literature and a consensus procedure involving 8 psoriasis experts.
Results In this part, the use of systemic treatment in different age groups, during pregnancy, in metabolic syndrome, in
patients with mental health problems, in different psoriasis subtypes and in previously systemically treated patients treat-
ment is discussed.
Conclusion Guidance on therapeutic choice in specific clinical situations in psoriasis is provided in order to facilitate
the decision-making in clinical practice.
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Introduction
The therapeutic arsenal of psoriasis has quickly risen to the
widest of any inflammatory skin disease. While this is very
promising for our patients, it complicates the ‘right’ personal-
ized therapeutic choice of the clinician. Due to the vast amount
of literature, it has even for psoriasis experts become almost
impossible to be aware of all studies that might be relevant in
each clinical context. Patient characteristics such as age, weight
or comorbidities such as diabetes or cardiovascular diseases may
interact with efficacy and/or development of adverse events. Spe-
cial psoriasis subtypes such as nail psoriasis, pustular psoriasis
and erythrodermic psoriasis require a different approach.
Despite evidence of efficacy, some drugs are licensed in all age
groups (e.g. children), and additionally, previous systemic drugs
may influence the outcome of subsequent treatment.
The BETA-PSO (Belgian Evidence-based Treatment Advice in
Psoriasis) project was initiated by the Royal Belgian Society of
Dermatology and Venerology (under the presidency of Jo
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Lambert, first author) with the intention to provide a practical
aid for dermatologists to facilitate a well-informed therapeutic
decision for each patient. Although the context and reimburse-
ment criteria of Belgium were taken into account, these recom-
mendations are likely to be valuable for all dermatologists
treating psoriasis patients worldwide.
In this project, relevant clinical questions on the treatment of
psoriasis were formulated and a systematic search was per-
formed. Subsequently, a group of 8 Belgian psoriasis experts dis-
cussed the data, rated the evidence and made specific
appropriate recommendations.
Material and methods
The clinical recommendations were developed using a quasi-
Delphi consensus methodology as follows: an expert group (EG)
of 8 Belgian dermatologists who treat patients with psoriasis,
discussed and agreed on the recommendation of the type of sys-
temic treatment which was considered to be advisable in a par-
ticular clinical context based on the existing evidence. The
experts identified during a full-day face-to-face meeting on 16
January 2019 a list of 38 questions related to real-world situa-
tions frequently faced by clinicians when managing patients with
psoriasis in their clinics.
Each expert was assigned a separate topic to summarize based
on a systematic search of the literature in PubMed. Articles (in-
cluding randomized controlled trials, case–control studies, obser-
vational studies, systematic reviews, meta-analyses, case reports
but excluding letters and opinion papers) on psoriasis patients
treated with systemic treatments for psoriasis (conventional, syn-
thetic and biological) were included that reported data on:
1 the influence of metabolic comorbidities on the outcome (ef-
ficacy on psoriasis, side-effects) or the influence of the treat-
ment on metabolic comorbidities
2 the influence of the treatment on specific clinical situations
such as nail psoriasis, erythrodermic psoriasis and pustular
psoriasis
3 the effect of being biological experienced or not
4 the influence of age on the outcome (efficacy, side-effects)
and the specific use of the considered drugs in defined age
groups (efficacy, side-effects)
5 the influence of the treatment on mental health
The following sixteen drugs for the systemic treatment of pso-
riasis were considered in this practical guidance:
• conventional antipsoriatic drugs: acitretin, cyclosporine,
dimethylfumarate, methotrexate
• synthetic antipsoriatic drugs: apremilast
• biological antipsoriatic drugs: tumour necrosis factor
(TNF) antagonists: adalimumab, certolizumab pegol, etan-
ercept, infliximab; interleukin (IL) 12/23 inhibitor: ustek-
inumab; IL23/p19 inhibitors: guselkumab, risankizumab,
tildrakizumab; IL17 receptor blocker: brodalumab; IL17
inhibitors: ixekizumab, secukinumab
Searches were performed on 27 November 2018 and were
restricted to publications during previous 5 years, in English
language. The search was simultaneously performed for all clini-
cal situations (BETA-PSO part 1 and 2) (Figure S1 and
Table S1). Additionally, SmPCs (Summary of Product Charac-
teristics) of the concerned drugs were screened. An updated lit-
erature search was performed 25 January 2019.
The studies identified through electronic searches were sub-
jected to screening of the title and abstracts to find relevant pub-
lications. During first pass, all the references were screened by
single analyst as per specified population, intervention, comor-
bidities and outcome (PICO) criteria provided in Table 1.
In addition to a comprehensive literature search of the avail-
able published evidence, pharmaceutical manufacturers of treat-
ments currently licensed in Belgium for the systemic treatment
of psoriasis were invited to provide the latest peer-reviewed pub-
lished materials on their drugs. The experts were allowed to add
any additional relevant articles if deemed necessary (e.g. if pub-
lished before 5 years).
The quality of the evidence (A: high, B: moderate and C: low)
and the strength of the recommendations (strong vs weak) were
categorized according to the Grading of Recommendations
Assessment Development and Evaluation (GRADE) criteria.1 A
high level of evidence (A) was given for data from well-sized ran-
domized clinical trials or extensive experience in clinical prac-
tice. Moderate evidence (B) was considered in case of
observational studies, small-sized randomized clinical trials or
moderate experience in clinical practice. Low evidence (C) was
attributed when only case series, retrospective studies without
controls were available or there was only limited experience in
clinical practice.
The outcome of the identified studies was classified as indicat-
ing (i) that the efficacy of the drug was preserved without caus-
ing increased adverse events or worsening of the comorbidity;
(ii) a limited risk of decreased efficacy of the drug and/or limited
risk of increased adverse events or worsening of the comorbidity,
(iii) a moderate risk of decreased efficacy of the drug and/or
moderate risk of increased adverse events or worsening of the
comorbidity and (iv) an important risk of decreased efficacy of
the drug and/or moderate risk of increased adverse events or
worsening of the comorbidity.
Subsequently, the 38 clinical questions were answered by
each expert via an online digital platform. The participants
were able to review all comments and the supporting pub-
lished evidence. For each clinical situation, the experts agreed
on a ‘strong’ or ‘weak’ recommendation in favour or against
the use of the concerned systemic treatments. The consoli-
dated answers generated were summarized into clinical recom-
mendations and reviewed by the expert group. The experts
were then invited to review wording of the draft clinical rec-
ommendations and to vote (agree/disagree) (8 March 2019 to
19 April 2019) concerning the final wording of the clinical
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recommendations. Where there was disagreement with the
draft wording, the chairperson contacted the expert to under-
stand and clarify the issue. The recommendation was then
amended on 17 September 2019 to all members’ satisfaction




Age Paediatric patients. In children below 12 years from an
efficacy and safety perspective, we recommend that the following
biological drugs, adalimumab and etanercept, and the conven-
tional systemic drugs, methotrexate and cyclosporine (short-
term use only), are used to treat paediatric psoriasis patients.
Some advisors report good results with acitretin therapy in pae-
diatric psoriasis patients, in doses of 0, 3–0 and 5 mg/kg. How-
ever, we advise caution when using acitretin due to occasional
reports of bone changes in children using retinoids.2 A far more
recent review of bone toxicity of retinoids in psoriasis (albeit not
in children) did not show evidence for bone toxicity.3
We do not recommend using infliximab in paediatric psoria-
sis patients due to higher reported rates of malignancies associ-
ated with infliximab use compared to the general paediatric
population.4
Some reports mention the use of fumarates although it is cur-
rently not licensed in this age group in Belgium.5
Although there is evidence to show that the synthetic
drug apremilast, the TNF inhibitor certolizumab pegol, the
IL17 inhibitors, brodalumab, ixekizumab and secukinumab;
the IL12/23 inhibitor ustekinumab (and other new biological
TABLE 1 Recommendations for systemic psoriasis treatments according to age and pregnancy/breastfeeding
ACIT, acitretin; ADA, adalimumab; APR, apremilast; BROD, brodalumab; CERT, certolizumab pegol; CYCLO, cyclosporin; ETA, etanercept; GUS, guselku-
mab; IFX, infliximab; IXE, ixekizumab; RIS, risankizumab; SEC, secukinumab; TIL, tildrakizumab; UST, ustekinumab.
†Unlicensed for this indication.
Strong recommendation 
in favour
Weak recommendation in 
favour
Weak recommendation 
against: evaluate risk 
versus benefit case by case
Strong recommendation 
against
Insufficient evidence to 
make a recommendation
“Will be efficacious and 
cause no specific harm in 
this patient group”
“Will likely be efficacious 
and likely cause no specific 
harm in this patient group”
“Might/may be less 
efficacious or might/may 
cause harm in this patient 
group”




ADA (>4 yr), ETA (> 6 yr)
ACIT
CYCLO FUM* IFX APR*
CERTO*
SEC*, IXE*, BROD*
UST*, GUS*, RIS*, TIL*
Adolescents
MTX, ACIT ( ), FUM
ADA, ETA, IFX
UST(> 12yr)





ACIT, MTX, CYCLO, FUM






CERTO ADA, ETA, IFX (not 3rd trim)
UST(not 3rd trim)
SEC (not 3rd trim)
CYCLO ACIT (3 yrs before)





ADA, CERTO, ETA, IFX
SECU, IXE, BROD
UST, GUS, TIL, RIS
ACIT, MTX, CYCL, FUM
APR




ADA, CERTO, ETA, IFX
SECU, IXE, BROD
UST, GUS, TIL, RIS
MTX (3 months before)
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drugs such as the IL23/p19 inhibitors: guselkumab, risankizu-
mab, tildrakizumab) are efficacious in paediatric patients, we
are – due to a lack of safety data – unable to recommend
their use in paediatric psoriasis patients at this point in
time. We also note that these drugs are not currently
licensed for use in this age group.
Based on the manufacturers’ information, we note that the
following age limits apply: adalimumab is recommended for the
treatment of psoriasis patients above 4 years and etanercept in
patients above 6 years of age.6,7
Adolescent patients. In young people with psoriasis, from an effi-
cacy and safety perspective, we recommend the biological drugs,
adalimumab, etanercept, infliximab and ustekinumab, and the
conventional drugs acitretin, cyclosporine (for short-term use
only), fumarates and methotrexate, for the treatment of adoles-
cent patients, 12–18 years.
However, we do not recommend acitretin in adolescent girls
with psoriasis due to the risk of teratogenicity and the need for
contraception for 3 years following stopping acitretin treatment.
Similar to paediatric patients, apremilast, the TNF inhibitor
certolizumab pegol, the IL17 inhibitors, brodalumab, ixek-
izumab and secukinumab, and the IL23/p19 inhibitors, guselku-
mab, risankizumab and tildrakizumab, can currently not be
recommend in these patients due to limited data and lack of
licence for use in children.
Based on the manufacturers’ information, we note that the
following age limits apply: ustekinumab is recommended for the
treatment of psoriasis patients greater than 12 years.8
Elderly patients. From a safety and efficacy perspective in elderly
psoriasis patients, we recommend the following biological drugs
adalimumab, certolizumab pegol, etanercept and infliximab;
brodalumab, ixekizumab and secukinumab; ustekinumab,
guselkumab, risankizumab, tildrakizumab and, the synthetic
drug, apremilast.
We also recommend the conventional drugs, methotrexate,
cyclosporine, and fumarates and acitretin are used to treat
patients (greater than 65 years) with psoriasis.
Pregnancy/Lactation Female patients of childbearing age. -
Based on the available placental transfer and pregnancy out-
comes evidence, our recommendation for female patients with
psoriasis wishing to conceive or who may be pregnant and where
treatment is clinically needed is to use of the Fc-free biological
drug certolizumab pegol as first-line treatment, followed by
either adalimumab or etanercept.9–11
However, the use of Fc-containing biologics (including etaner-
cept, adalimumab) during the third trimester is not recom-
mended. We also advise that infliximab, secukinumab,
ixekizumab, brodalumab and ustekinumab may be used in
female patients wishing to conceive; however, data are limited
with these biological drugs.12–14
Regarding the conventional drugs, cyclosporine should not be
used during pregnancy unless the potential benefit to the mother
justifies the potential risk to the foetus.15 We also recommend
that female psoriasis patients who may wish to conceive to have
completed acitretin treatment at least 3 years before conception
due to the high teratogenicity risk associated with this drug.
Likewise, we advise female patients to complete treatment with
fumarates and methotrexate for at least 6 months before con-
ception.16,17 Regarding the newer biological drugs, we note from
the manufacturer’s information that pregnancy should be
avoided for 17 weeks after treatment with tildrakizumab, for
12 weeks with guselkumab and for 21 weeks with risankizu-
mab.18 Finally, apremilast is contraindicated in female psoriasis
patient wishing to conceive or who may be pregnant. This is
based on animal data indicating apremilast can cause foetal loss
in mice and monkeys.19
Breastfeeding. From a safety perspective, we advise that the
majority of the biological drugs may be safely used to treat
female psoriasis patients who are also breastfeeding, as they are
denatured in the gastro-intestinal tract of the infant.20
Apremilast, and fumarates, methotrexate, cyclosporine and
acitretin are contraindicated during lactation due to adverse risk
posed to the feeding infant. Therefore, we recommend that they
should be avoided while breastfeeding.
Males wishing to conceive. From a safety perspective, we recom-
mend that cyclosporine, acitretin and apremilast and fumarates
can be used to treat male psoriasis patients who are wishing to
conceive. The only formal contraindication is methotrexate with
a recommendation to stop 6 months prior to conception. How-
ever, this is not evidenced by clear data on paternal-mediated
teratogenicity.21
On the use of biologics (TNF inhibitors, IL17 blockers, IL17
receptor blocker and IL23 blockers) in males wishing to con-
ceive, there is currently no clear evidence pointing to an
increased risk.22
Mental health Psychiatric disorders. Patients with psoriasis are
more affected by depression, anxiety, suicidal ideation behaviour
(SIB), lack of confidence, insomnia and poor quality of life
(QOL), and we also know that these symptoms are reduced with
effective treatment in these patients.23 Therefore, we recommend
that the rapidity of onset of action with effective treatment to
improve the QOL in psoriasis patients with psychiatric issues
may be an advantage. Large studies showed a sustained benefit
of biologics in reducing antidepressant use among psoriasis
patients. The beneficial effect was more significant with continu-
ous treatment.24,25 Biological treatments seem more effective in
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reducing depression and insomnia than DMARDs.24,26 However,
there is a lack of robust comparative data between the different
biological drugs. Although adalimumab, etanercept and ustek-
inumab were associated with a statistically significant reduction
in depressive symptoms, comparison between the drugs could
not be made due to different rating scales being used.27 One
study found greater improvements in anxiety and depression
with guselkumab vs adalimumab.23 Studies have shown that the
IL-17 antagonists, secukinumab and ixekizumab improve
patients’ QOL and alleviate depression in 40% patients, respec-
tively.28,29 Fumarates have also been shown to reduce depressive
symptoms in patients.30
The TNF antagonists: infliximab, adalimumab, certolizumab
pegol and etanercept; the IL12/23 inhibitor: ustekinumab; the
IL23/p19 inhibitors: guselkumab, risankizumab and tildrak-
izumab; the IL17 inhibitors: secukinumab and ixekizumab; and
conventional drugs, including methotrexate, cyclosporin, fuma-
rates and acitretin, have been shown to be effective when used as
systemic treatments for psoriasis patients with psychiatric issues
such as depression.
Although the AMAGINE studies also confirm the improve-
ment of patients’ quality of life with brodalumab, we would
advise caution, however, when using the IL17 receptor blocker,
brodalumab, in patients with a history of depression as suici-
dal behaviour has been reported in patients treated with an
FDA-mandated black box warning regarding suicide.31 How-
ever, the EMA, Health Canada and the FDA, as well as recent
reports, cannot confirm a causal relationship between bro-
dalumab and suicidal ideation and behaviour.32 We would
also advise caution using the synthetic drug, apremilast, due
to an increased risk of psychiatric disorders. Despite several
studies showing an improvement in patients’ QOL with treat-
ment, an increased risk of mental disorders has been associ-
ated with its use in psoriasis patients.33–35 The risks and
benefits of starting or continuing treatment with apremilast
should be carefully assessed whether patients report previous
or existing psychiatric symptoms or whether concomitant
treatment with other medicinal products likely to cause psy-
chiatric events is intended.19
Metabolic disorders Metabolic syndrome. We advise that the
TNF antagonists: adalimumab, certolizumab pegol, etanercept
and infliximab; the IL12/23 inhibitor: ustekinumab; the IL23/
p19 inhibitors: guselkumab, risankizumab and tildrakizumab;
the IL17 receptor blocker: brodalumab; the IL17 inhibitors: ixek-
izumab and secukinumab; as well as the synthetic small molecule
drug, apremilast, and the conventional drugs, methotrexate,
cyclosporine, fumarates and acitretin can all be used as systemic
treatments for adult psoriasis patients with metabolic syndrome.
This is primarily because they provide effective treatment to
reduce the symptoms of psoriasis and improve patients’ quality
of life. Secondly, some of the drugs might also offer some
beneficial impact on the cardiovascular risk factors associated
with the metabolic syndrome.36
There is currently an ongoing debate concerning improve-
ment in physiological measures of metabolic syndrome resulting
from various newer treatments such as TNF inhibitors for psori-
asis. In fact, weight may increase in patients with their use.37
Specifically, with cyclosporine treatment, atherogenic dyslipi-
daemia, arterial hypertension and glucose intolerance may wor-
sen, and with acitretin use, atherogenic dyslipidaemia may
worsen. In patients with increased risk for liver or renal toxicity,
caution is also recommended for methotrexate.38 Therefore, we
recommend careful monitoring and follow-up of patients trea-
ted with these drugs.
We also advise increased surveillance of the markers of meta-
bolic syndrome in psoriasis patients including increasing waist-
line, elevated blood pressure, raised triglyceride levels, reduced
HDL cholesterol and raised fasting glycemia. We also advise
patients with metabolic syndrome receive obesity management
and smoking cessation advice, as relevant.
Type II diabetes and/or insulin resistance. From a safety per-
spective, none of the biological and non-biological systemic
treatments available for patients with psoriasis are specifically
contraindicated in those patients who also have type 2 dia-
betes and/or insulin resistance. It is difficult to make mean-
ingful clinical recommendations due to a lack of comparative
data between these drugs. Some studies suggest that the use
of anti-TNF drugs, such as infliximab, adalimumab, cer-
tolizumab pegol and etanercept, is associated with decreased
insulin resistance.39–41 Another study, however, has shown no
benefit with anti-TNF drugs in combination with methotrex-
ate versus methotrexate alone on HbA1C or fasting blood
glucose in psoriasis patients.42 Methotrexate and acitretin
have also been linked to a decreased insulin resistance in
psoriasis.43 We do advise caution with the use of cyclosporine
and methotrexate in these patients due to an increased risk
of liver and renal toxicity.38
All of the systemic treatments considered can be used to treat
psoriasis patients who also have type 2 diabetes and/or insulin
resistance. We advise that the TNF antagonists: adalimumab,
certolizumab pegol, etanercept and infliximab; the IL12/23 inhi-
bitor: ustekinumab; the IL23/p19 inhibitors: guselkumab, risan-
kizumab and tildrakizumab; the IL17 receptor blocker:
brodalumab; the IL17 inhibitors: ixekizumab and secukinumab;
as well as the synthetic drug, apremilast, and the conventional
drugs, fumarates and acitretin, can be used as systemic treat-
ments for psoriasis patients with type II diabetes and/or insulin
resistance. Cyclosporine and methotrexate can also be used
although more caution is advisable.
Obesity. For obese psoriasis patients, we advise that the TNF
antagonists: adalimumab, certolizumab pegol, etanercept and
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infliximab; the IL12/23 inhibitor: ustekinumab; the IL23/p19
inhibitors: guselkumab, risankizumab and tildrakizumab; the
IL17 receptor blocker: brodalumab; the IL17 inhibitors: ixek-
izumab and secukinumab; as well as the synthetic drug, apremi-
last, and the conventional drugs, fumarates and acitretin, be
used as systemic treatments. Diet interventions should be
encouraged as they result in improved treatment outcomes using
biologic therapy.44
From an efficacy perspective, studies have shown that the bio-
logical drugs, ustekinumab, infliximab, adalimumab and etaner-
cept, and most conventional drugs require higher dosing in
obese psoriatic patients, compared with healthy-weight patients.
Therefore, it is our opinion that weight-adjusted dosing with
these drugs may be required in obese patients. Currently, only
infliximab and ustekinumab allow a specific higher dosing by
weight.45,46 Nonetheless, this trend is not yet clear with the
newer biologics. Latest trial data on risankizumab, guselkumab,
ixekizumab and brodalumab show a less pronounced effect of
weight on their efficacy.47–50 A few studies have reported an
increase in weight associated with treatment with some of the
biologics (such as TNF antagonists) although results remain
contradictory to date.51,52 Apremilast rather leads to weight
loss.53
From a safety perspective, we advise caution, however, with
weight-dependent dosing of the conventional drugs, methotrex-
ate and cyclosporine, due to increased risk of renal and liver tox-
icities associated with increased dosing.
Cardiovascular risk factors. It is well known that psoriasis
patients have an elevated risk of atherosclerosis, characterized by
endothelial dysfunction. The features of metabolic syndrome,
including hypertension and dyslipidaemia, are associated with
endothelial activation in patients with moderate-to-severe psori-
asis.
In patients with psoriasis and cardiovascular risk factors, we
advise that the biologics including adalimumab, certolizumab
pegol, etanercept and infliximab; ustekinumab; guselkumab,
risankizumab and tildrakizumab; brodalumab; ixekizumab and
secukinumab; as well as the synthetic drug, apremilast, and the
conventional drugs, including cyclosporine, methotrexate, fuma-
rates and acitretin, can be used from an efficacy and safety per-
spective as systemic treatment.
We suggest that the TNF antagonist drugs are primarily used
to treat psoriasis patients with cardiovascular risk factors. Stud-
ies show that adalimumab therapy leads to a reduction in the
endothelial activation biomarker, soluble (s) E-selectin (sE-se-
lectin) levels, and a decrease in intima–media thickness as an
indicator of atherosclerosis has been reported.54,55 Nonetheless,
only few preliminary findings suggest a clinical significance.56
No difference in cardiovascular events or atrial fibrillation was
found between TNFi therapy and ustekinumab was found in a
large cohort study.57 There is also evidence to suggest that the
anti-IL17 drug, secukinumab, might have a beneficial effect on
CV risk by improving the endothelial function of patients with
psoriasis.58 A recent observational study shows that biologic
therapy in severe psoriasis was associated with favourable modu-
lation of coronary plaque indices by coronary computed tomog-
raphy angiography.59 These findings highlight the importance of
systemic inflammation in coronary artery disease and larger,
randomized trials with all the biological drugs are required.
We advise caution with cyclosporine and acitretin treatment
in psoriasis patients with cardiovascular risk factors as they have
been shown to increase the risk of hypertension and dyslipi-
daemia, and hyperlipidaemia alone, respectively. However, these
side-effects are manageable with appropriate treatment and
should not form a formal contraindication for its use.
We note that several of the anti-TNF drugs are contraindi-
cated in psoriasis patients with moderate or severe heart failure
(NYHA class III/IV) including adalimumab, certolizumab pegol
and infliximab and that the entire class should be used with cau-
tion in patients with mild heart failure (NYHA class I/II).
Non-alcoholic fatty liver disease. From an efficacy and safety per-
spective, most biological and non-biological systemic drugs for
psoriasis can be used effectively to treat psoriasis patients who
also have non-alcoholic fatty liver disease. However, there is no
evidence to show whether one of the listed drugs is more or less
efficacious compared with another in a patient with psoriasis
and fatty liver disease. This is due to a lack of comparative stud-
ies between the drugs in this patient group.
In psoriasis patients with non-alcoholic fatty liver disease, we
recommend that the biological drugs, infliximab, adalimumab,
certolizumab pegol and etanercept; ustekinumab, guselkumab,
risankizumab and tildrakizumab; brodalumab, ixekizumab and
secukinumab; the synthetic drug, apremilast; and the conven-
tional drug, cyclosporine, are used from an efficacy and safety
perspective.
From a safety perspective, methotrexate has been shown to
cause elevated liver function tests in patients. Caution is war-
ranted with methotrexate but also with fumarates and acitretin.
This is because methotrexate has been shown to increase liver
function tests in these patients, although no cases of liver failure
have been observed with methotrexate treatment.60 Several cases
of liver toxicity have been described with fumarates in patients
with multiple sclerosis although severe liver injury has not been
reported in psoriasis.61,62 Regarding acitretin, serum aminotrans-
ferase elevation has been noted, but is usually self-limiting.63
Psoriasis subtypes Nail psoriasis. From an efficacy perspec-
tive, we recommend in psoriasis patients with nail disease the
TNF antagonists: infliximab, adalimumab, certolizumab pegol
and etanercept; the IL12/23 inhibitor: ustekinumab; the IL23/
p19 inhibitors: guselkumab and risankizumab; the IL17 receptor
blocker: brodalumab; the IL17 inhibitors: ixekizumab and
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secukinumab; and the synthetic drug, apremilast.64–67 Also, the
conventional drugs dimethylfumarate, cyclosporine and
methotrexate are used based on clinical trial data. There is less
robust evidence supporting the use of the conventional drugs
cyclosporin, methotrexate and acitretin; however, it is our opin-
ion that these drugs also provide benefit to psoriasis patients
with nail disease especially in patients with limited skin involve-
ment (PASI/BSA < 10).68 There is also limited evidence sup-
porting the use of dimethylfumarate.69 There was no
recommendation of the experts on the use of tildrakizumab in
these patients, mainly due to a paucity of supporting data.
Generalized pustular psoriasis (GPP). We recommend the use of
acitretin for the treatment of patients with generalized pustular
psoriasis (GPP), as it is the only drug licensed for this indication.
There is also evidence supporting the use of methotrexate, adali-
mumab, ixekizumab, secukinumab, brodalumab and guselkumab
to treat GPP patients and, based on our collective experience, we
advise their use in these patients.70–74 There is less robust evidence
based on limited case series and case reports supporting the use of
infliximab, etanercept, ustekinumab, risankizumab, tildrak-
izumab, apremilast and cyclosporine in GPP patients.75,76 We do
not recommend the use of fumarates in the systemic treatment of
GPP patients, due their slow mode of action and potential hyper-
sensitivity reactions worsening the disease.
Erythrodermic psoriasis. We agree that cyclosporine and inflix-
imab appear to be the most rapidly acting agents for the treat-
ment of erythrodermic psoriasis. Acitretin and methotrexate are
also appropriate first-line choices, although they usually work
more slowly.77
There is also clinical evidence supporting the use of the bio-
logical IL12/23 inhibitor, ustekinumab for the treatment of ery-
throdermic psoriasis.78,79 Beneficial results with secukinumab,
ixekizumab, brodalumab, guselkumab, adalimumab, etanercept,
apremilast and cyclosporine have been observed to treat erythro-
dermic psoriasis patients. However, this is based on some pub-
lished open-label studies and case series mostly in Japanese
patients.72–74,80 Based on our collective experience, we advise
their use. No data on use of risankizumab nor tildrakizumab
were found.
We do not recommend the use of fumarates, however, in the
systemic treatment of erythrodermic psoriasis patients, due to
their slow mode action and potential hypersensitivity reactions
worsening the disease.
Practical use of biologics Biologic-experienced patients. In bio-
logic-experienced patients, drug survival is better if switch is per-
formed between as opposed to within biologic classes.81
However, in case a deliberate choice was made for a certain bio-
logic class based on efficacy, side-effects or comorbidities, evi-
dence indicates that switch within class is also a good option if a
biologic with a higher efficacy is chosen.82 The general consensus
of the expert discussion was to consider a switch to another bio-
logic class or to opt for the biologic within the same class
exhibiting the highest efficacy in clinical trials. Overall, recent
data suggest that newer biologics are less affected by a history of
previous failure to another biologic.83
Intermittent treatment. Regarding biologics, we recommend
continuous systemic treatment for patients with psoriasis when
the patient is still receiving benefit. Should a psoriasis patient
wish to stop and then restart systemic treatment, we advise that
it is possible to do so, particularly with etanercept and ustek-
inumab.84,85 Conventional drugs and synthetic drug apremilast
seem well suited for intermittent treatment. There is robust evi-
dence that demonstrates these drugs can be stopped and then
restarted with equivalent efficacy and without increased risk of
flare of disease. For adalimumab, certolizumab pegol, guselku-
mab, risankizumab and tildrakizumab, ixekizumab, secuk-
inumab and brodalumab, the evidence is less clear. Fumarates
can also be used intermittently although they exhibit a slow
onset of action.86 This observation is based on our collective
opinion and experience.
There is currently insufficient evidence to support stopping
and then restarting treatment with other biological drugs,
including adalimumab, certolizumab pegol and tildrakizumab.
We advise caution with this approach until these data are avail-
able. For guselkumab, risankizumab, ixekizumab and secuk-
inumab, promising results when retreating after drug
withdrawal were obtained in clinical trial settings indicating that
intermittent treatment might be an option with the newer IL23/
p19 inhibitors and IL17 blockers.87,88
However, we recommend against stopping and restarting
infliximab due to reduced efficacy on restarting treatment as a
result of the development of antidrug antibodies. From a safety
perspective, there is also an increased risk of serious infusion
reactions with intermittent infliximab dosing.46,89
Use of biosimilars. From an efficacy and safety perspective, we
advise that it is possible to switch from TNF antagonist reference
drugs, infliximab, adalimumab and etanercept, to their respec-
tive biosimilar.90 However, this advice is based on some but not
all of the groups’ experience with switching.
Discussion
Systemic psoriasis treatments result in a variable clinical efficacy
and adverse event rate depending on pre-existing patients’ char-
acteristics. The decision aid based on the current evidence in
Tables 1, 2 and 3 can be a valuable tool in clinical practice to
guide the therapeutic choice. Unfortunately, evidence is in a sub-
stantial part limited to ‘level C’, indicating case series, case
reports or limited experience in clinical practice. In case of new
biologics, data are often still lacking. Head-to-head comparison
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Weak recommendation in 
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Weak recommendation 
against: evaluate risk 




Insufficient evidence to 
make a recommendation
“Will be efficacious and 
cause no specific harm in 
this patient group”
“Will likely be efficacious 
and likely cause no specific 
harm in this patient group”
“Might/may be less 
efficacious or might/may 
cause harm in this patient 
group”
“Likely to cause harm in this 
patient group”
Psychiatric disorders
ACIT, MTX, CYCLO, FUM
ADA, CERT, ETA, IFX







ADA, CERT, ETA, IFX
UST, GUS, RIS, TIL
SEC, IXE, BROD
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of drugs is very limited, especially in less common disease pre-
sentations such as generalized pustular psoriasis. Nonetheless,
obvious ‘red’ and ‘orange’ flags should be recognized by every
physician before a treatment is initiated.
Regarding age, many drugs are not licensed for use in children
such as ustekinumab (>12 years), fumarates or apremilast
(>18 years). Some experts chose acitretin as first choice in order
to avoid long-term immunosuppressive effects despite the con-
cern of bone changes based on data with long-term use of etreti-
nate.2 Older age, pre-existing renal or liver injury may increase
the risk of adverse events of conventional drugs such as
methotrexate and cyclosporin.91 Furthermore, the risk of drug–
drug interactions is increased in (elderly) patients with polyphar-
macy using methotrexate or cyclosporine and apremilast.19,92
ACIT, acitretin; ADA, adalimumab; APR, apremilast; BROD, brodalumab; CERT, certolizumab pegol; CYCLO, cyclosporin; ETA, etanercept; GUS, guselku-
mab; IFX, infliximab; IXE, ixekizumab; RIS, risankizumab; SEC, secukinumab; TIL, tildrakizumab; UST, ustekinumab.
Green: will be efficacious and cause no specific harm in this patient group; Light green: will likely be efficacious and likely cause no specific harm in this patient
group; Orange: might/may be less efficacious or might/may cause harm in this patient group; Red: likely to cause harm in this patient group; Grey: insufficient
evidence to make a recommendation.
Strong recommendation 
in favour
Weak recommendation in 
favour
Weak recommendation 
against: evaluate risk 




Insufficient evidence to 
make a recommendation
“Will be efficacious and 
cause no specific harm in 
this patient group”
“Will likely be efficacious 
and likely cause no specific 
harm in this patient group”
“Might/may be less 
efficacious or might/may 
cause harm in this patient 
group”























Table 3 Evidence of systemic treatments for psoriasis in different clinical conditions
Levels of evidence: A (high level of evidence), B (moderate level of evidence), C (low level of evidence).
Results of the studies: 1. Green: preserved efficacy without increased adverse events or worsening of the comorbidity; 2. Yellow: limited risk of decreased effi-
cacy and/or limited risk of increased adverse events or worsening of the comorbidity, 3. Orange: moderate risk of decreased efficacy and/or moderate risk of
increased adverse events or worsening of the comorbidity, 4. Red: important risk of decreased efficacy and/or moderate risk of increased adverse events or
worsening of the comorbidity.
ACIT, acitretin; ADA, adalimumab; APR, apremilast; BROD, brodalumab; CERT, certolizumab pegol; CYCLO, cyclosporin; ETA, etanercept; GUS, guselku-
mab; IFX, infliximab; IXE, ixekizumab; RIS, risankizumab; SEC, secukinumab; TIL, tildrakizumab; UST, ustekinumab.
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In metabolic syndrome, several conventional drugs including
cyclosporine, acitretin and methotrexate exhibit an unfavourable
effect on lipids, hypertension and liver injury. However, as most
issues are manageable by accurate intervention (e.g. diet, statins,
antihypertensive medication), this does not preclude their use.
Nonetheless, apremilast and biologics seem often a more favour-
able choice in patients with metabolic syndrome.
No clear data have shown a convincing different response of
systemic treatments in nail psoriasis compared to psoriasis vul-
garis. However, a BSA and/or PASI> 10 is often not reached in
patients with nail psoriasis limiting the use of biologics in these
patients. In Belgium, an extensive BSA involvement is not a
requirement for reimbursement of fumarates which makes it a
reasonable option despite limited reports on nail psoriasis.
Pustular and erythrodermic psoriasis display a different disease
pattern requiring a tailored approach. Acitretin is the only licensed
drug in generalized pustular psoriasis, although often combination
therapy with corticosteroids is necessary, and it is contraindicated
in women of childbearing age. Regarding erythrodermic psoriasis,
one expert raised the concern of the differential diagnosis with
cutaneous T-cell lymphoma. In the latter case, acitretin may be the
safest option until the final diagnosis is established.
A limitation of these recommendations is that only the view-
point of dermatologists was taken into account. The expert
group emphasized the need for a multidisciplinary approach in
patients with important comorbidities. These guidelines do not
replace the need for shared decision-making as patients may bal-
ance efficacy versus side-effects differently.
Given the rapid evolution of the therapeutic landscape of pso-
riasis, readers should be aware that this project is a living guide-
line that will require a regular update based on new data. This is
certainly the case for the new class of specific IL-23 inhibitors
which have currently limited available data.
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